Cargando…

European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation

Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hamper...

Descripción completa

Detalles Bibliográficos
Autores principales: Berenguer, Marina, de Martin, Eleonora, Hessheimer, Amelia J., Levitsky, Josh, Maluf, Daniel G., Mas, Valeria R., Selzner, Nazia, Hernàndez-Èvole, Helena, Lutu, Alina, Wahid, Nabeel, Zubair, Haseeb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498996/
https://www.ncbi.nlm.nih.gov/pubmed/37711401
http://dx.doi.org/10.3389/ti.2023.11358
_version_ 1785105631634522112
author Berenguer, Marina
de Martin, Eleonora
Hessheimer, Amelia J.
Levitsky, Josh
Maluf, Daniel G.
Mas, Valeria R.
Selzner, Nazia
Hernàndez-Èvole, Helena
Lutu, Alina
Wahid, Nabeel
Zubair, Haseeb
author_facet Berenguer, Marina
de Martin, Eleonora
Hessheimer, Amelia J.
Levitsky, Josh
Maluf, Daniel G.
Mas, Valeria R.
Selzner, Nazia
Hernàndez-Èvole, Helena
Lutu, Alina
Wahid, Nabeel
Zubair, Haseeb
author_sort Berenguer, Marina
collection PubMed
description Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hampers post-LT outcomes. An optimal approach to immunosuppression (IS), including safe weaning, may benefit patients by mitigating the effect on recurrent diseases, as well as reducing adverse events associated with over-/under-IS, including chronic kidney disease (CKD). Prediction of these outcome measures—disease recurrence, CKD, and immune status—has long been based on relatively inaccurate clinical models. To address the utility of new biomarkers in predicting these outcomes in the post-LT setting, the European Society of Organ Transplantation (ESOT) and International Liver Transplant Society (ILTS) convened a working group of experts to review literature pertaining to primary disease recurrence, development of CKD, and safe weaning of IS. Summaries of evidence were presented to the group of panelists and juries to develop guidelines, which were discussed and voted in-person at the Consensus Conference in Prague November 2022. The consensus findings and recommendations of the Liver Working Group on new biomarkers in LT, clinical applicability, and future needs are presented in this article.
format Online
Article
Text
id pubmed-10498996
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104989962023-09-14 European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation Berenguer, Marina de Martin, Eleonora Hessheimer, Amelia J. Levitsky, Josh Maluf, Daniel G. Mas, Valeria R. Selzner, Nazia Hernàndez-Èvole, Helena Lutu, Alina Wahid, Nabeel Zubair, Haseeb Transpl Int Health Archive Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hampers post-LT outcomes. An optimal approach to immunosuppression (IS), including safe weaning, may benefit patients by mitigating the effect on recurrent diseases, as well as reducing adverse events associated with over-/under-IS, including chronic kidney disease (CKD). Prediction of these outcome measures—disease recurrence, CKD, and immune status—has long been based on relatively inaccurate clinical models. To address the utility of new biomarkers in predicting these outcomes in the post-LT setting, the European Society of Organ Transplantation (ESOT) and International Liver Transplant Society (ILTS) convened a working group of experts to review literature pertaining to primary disease recurrence, development of CKD, and safe weaning of IS. Summaries of evidence were presented to the group of panelists and juries to develop guidelines, which were discussed and voted in-person at the Consensus Conference in Prague November 2022. The consensus findings and recommendations of the Liver Working Group on new biomarkers in LT, clinical applicability, and future needs are presented in this article. Frontiers Media S.A. 2023-08-30 /pmc/articles/PMC10498996/ /pubmed/37711401 http://dx.doi.org/10.3389/ti.2023.11358 Text en Copyright © 2023 Berenguer, de Martin, Hessheimer, Levitsky, Maluf, Mas, Selzner, Hernàndez-Èvole, Lutu, Wahid and Zubair. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Health Archive
Berenguer, Marina
de Martin, Eleonora
Hessheimer, Amelia J.
Levitsky, Josh
Maluf, Daniel G.
Mas, Valeria R.
Selzner, Nazia
Hernàndez-Èvole, Helena
Lutu, Alina
Wahid, Nabeel
Zubair, Haseeb
European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation
title European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation
title_full European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation
title_fullStr European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation
title_full_unstemmed European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation
title_short European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation
title_sort european society for organ transplantation consensus statement on biomarkers in liver transplantation
topic Health Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498996/
https://www.ncbi.nlm.nih.gov/pubmed/37711401
http://dx.doi.org/10.3389/ti.2023.11358
work_keys_str_mv AT berenguermarina europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation
AT demartineleonora europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation
AT hessheimerameliaj europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation
AT levitskyjosh europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation
AT malufdanielg europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation
AT masvaleriar europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation
AT selznernazia europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation
AT hernandezevolehelena europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation
AT lutualina europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation
AT wahidnabeel europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation
AT zubairhaseeb europeansocietyfororgantransplantationconsensusstatementonbiomarkersinlivertransplantation